Guillain-Barré Syndrome in an Australian State Using Both mRNA and Adenovirus-Vector SARS-CoV-2 Vaccines
Ann Neurol
.
2021 Nov;90(5):856-858.
doi: 10.1002/ana.26218.
Epub 2021 Sep 28.
Authors
Joshua Osowicki
#
1
2
3
,
Hannah Morgan
#
1
,
Adele Harris
1
,
Nigel W Crawford
1
2
3
,
Jim P Buttery
1
2
3
4
,
Lynette Kiers
5
6
Affiliations
1
Surveillance of Adverse Events Following Vaccination In the Community (SAEFVIC), Murdoch Children's Research Institute, Melbourne, VIC, Australia.
2
Department of General Medicine, Royal Children's Hospital Melbourne, Melbourne, VIC, Australia.
3
Department of Paediatrics, The University of Melbourne, Melbourne, VIC, Australia.
4
Centre for Health Analytics, Royal Children's Hospital Melbourne, Melbourne, VIC, Australia.
5
Department of Neurology, Royal Melbourne Hospital, Melbourne, VIC, Australia.
6
Department of Medicine, Faculty of Medicine, Health and Dentistry, The University of Melbourne, Melbourne, VIC, Australia.
#
Contributed equally.
PMID:
34528279
PMCID:
PMC8652921
DOI:
10.1002/ana.26218
No abstract available
Publication types
Letter
Comment
MeSH terms
Adenoviridae
Australia
COVID-19 Vaccines
COVID-19*
Guillain-Barre Syndrome*
Humans
RNA, Messenger
SARS-CoV-2
Substances
COVID-19 Vaccines
RNA, Messenger